CUE — Cue Biopharma Income Statement
0.000.00%
- $37.43m
- $13.65m
- $5.49m
- 27
- 18
- 25
- 13
Annual income statement for Cue Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3.46 | 3.15 | 14.9 | 1.25 | 5.49 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 40.2 | 48.2 | 58.7 | 54.5 | 57.6 |
Operating Profit | -36.8 | -45 | -43.7 | -53.2 | -52.1 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -36.3 | -44.6 | -43.7 | -53 | -50.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -36.7 | -44.8 | -44.2 | -53 | -50.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -36.7 | -44.8 | -44.2 | -53 | -50.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -36.7 | -44.8 | -44.2 | -53 | -50.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.66 | -1.56 | -1.41 | -1.49 | -1.11 |